hemophilia A


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to hemophilia A: hemophilia B, Hemophilia C
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hemophilia A - hemophilia caused by a congenital deficiency of factor VIII; occurs almost exclusively in men
bleeder's disease, haemophilia, hemophilia - congenital tendency to uncontrolled bleeding; usually affects males and is transmitted from mother to son
References in periodicals archive ?
Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Patients suffering from hemophilia A has a mutation for factor VIII in the gene and patients suffering from hemophilia B have a mutation due to the absence of clotting factor IX.
The "Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.
* Long-term follow-up from four phase III studies (HAVEN studies) shows Hemlibra's sustained efficacy and safety in people with hemophilia A, with and without factor VIII inhibitors.
[ClickPress, Thu Jul 04 2019] Manufacturers such as Roche has recently acquired Spark Therapeutics for its long term investment hemophilia A gene therapy market.
There are two types of diseases like hemophilia A and hemophilia B, he said adding that the disease can transform into boy babies from their mothers.
M2 PHARMA-February 4, 2019-Chugai's Hemlibra Gains Positive CHMP Opinion in Severe Hemophilia a Without Inhibitors
is the number of live male births diagnosed with hemophilia A.
M2 EQUITYBITES-September 3, 2018-Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A
Global Banking News-September 3, 2018-Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A
Patients with known bleeding disorders other than Hemophilia A, liver disease, co morbid and using aspiring were excluded from the study.
Genentech, a member of the Roche Group, announced that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors, were published in the August 30, 2018, issue of the New England Journal of Medicine.